Through the deal, Noble said it will develop novel demonstrators based on BD’s UltraSafe technology to improve access to new services for pharma partners, supporting product launches and patient experiences.
The companies said the combination of Noble’s market research and BD’s passive needle stick safety devices will allow for fully customized drug delivery devices with access to dedicated onboarding systems in one location.
“Demonstration devices can be instrumental in helping patients overcome fear and anxiety when using an injectable drug delivery device. However, our research has shown that for onboarding to be successful, the demonstrating device must be meticulously engineered to mimic the exact look and feel of the actual drug delivery device. In a recent market survey, we found that 89% of patients reported it’s very important to have the most realistic demonstrating device possible. By having a deep understanding of complex device engineering and patient needs, we can better help our partners like BD create impactful onboarding solutions,” Noble exec VP Craig Baker said in a prepared statement.
Noble said that all demonstrators are tested to guarantee needle simulation and plunger speeds to mimic real drug delivery devices.
“This collaboration represents the latest commitment to our ongoing expansion of the BD UltraSafe Needle Guard portfolio, as BD continues to increase the capabilities of the platform within the injectable biopharmaceutical market. With the increased use of the BD UltraSafe Passive and BD UltraSafe Plus Passive Needle Guards by patients who self-inject doctor prescribed medications, there is a need to provide a solution to our pharmaceutical partners to support patient onboarding. Noble’s systems deliver a viable option that leverages strong expertise for patients and broadens BD’s overall offering in demonstration devices,” BD safety & shielding systems VP Patrick Jeukenne said in a press release.